Startups
Medicine and pharmaceutical operating company. Corporate investment participation does not identify a standalone venture capital firm.
Team
No team members on record yet.
Investments
| $50M2026-01-27 |  TRexBio | Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Delos Capital, Avego BioScience Capital, Janus Henderson Investors |
| $33M2026-01-12 |  Juvena Therapeutics | Bison Ventures, Jefferson Life Sciences, Eli Lilly and Company, Mubadala Capital, Manta Ray |
| $65M2025-11-13 |  Gate Bioscience | ARCH Venture Partners, GV, Forbion, Versant Ventures, Eli Lilly and Company, Vineeta Agarwala |
| $45M2025-05-13 |  Stylus Medicine | Khosla Ventures, RA Capital Management, Eli Lilly and Company, Chugai Venture Fund |
| $84M2024-11-13 | TRexBio | Delos Capital, Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Avego BioScience Capital, Agent Capital |
| $14M2024-10-16 |  SunBird Bio | S32, EDBI, Polaris Partners, Eli Lilly and Company, ClavystBio, Section 32 |
| $10M2024-07-26 |  RetiSpec | iGan Partners, Verge HealthTech Fund, Eli Lilly and Company, Alzheimer's Drug Discovery Foundation |
| $40M2023-02-06 |  IGGENIX | Khosla Ventures, Alexandria Venture Investments, Eli Lilly and Company, Global Brain Corporation, Samir Kaul |
| $85M2022-03-08 | TRexBio | Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Laurion Capital Management |
| $15M2021-11-18 |  Fountain Therapeutics | Khosla Ventures, Alexandria Venture Investments, Eli Lilly and Company |
| $139M2021-04-13 |  Jaguar Gene Therapy | ARCH Venture Partners, The Goldman Sachs Group, Inc., Eli Lilly and Company, Deerfield |
| $139M2021 | Jaguar Gene Therapy | ARCH Venture Partners, The Goldman Sachs Group, Inc., Eli Lilly and Company, Deerfield |
| $31M2018-08-14 |  Magnolia Neurosciences | ARCH Venture Partners, Alexandria Venture Investments, AbbVie, Eli Lilly and Company, Partnership Fund for New York City, Pfizer Ventures |
| $48M2016-01-06 |  Petra Pharma | ARCH Venture Partners, Alexandria Venture Investments, AbbVie, Eli Lilly and Company, Partnership Fund for New York City, Pfizer Ventures |
| $65MUnknown date |  Gate Bio | ARCH Venture Partners, GV, Forbion, Versant Ventures, Eli Lilly and Company, Andreessen Horowitz (a16z) Bio + Health |
| $90MUnknown date |  Syndeio Biosciences | ARCH Venture Partners, Catalio Capital Management, AbbVie, Eli Lilly and Company, Palo Santo, Tenmile |
| $60MUnknown date |  Volastra Therapeutics | ARCH Venture Partners, Catalio Capital Management, Polaris Partners, Cormorant Asset Management, Eli Lilly and Company |